Phase 2 B-cell Malignancies Clinical Trials
8 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–8 of 8 trials
Recruiting
Phase 2
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Chronic Lymphocytic LeukemiaB-cell Malignancies
Curis, Inc.108 enrolled11 locationsNCT07271667
Recruiting
Phase 1Phase 2
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
B-cell Malignancies
AstraZeneca174 enrolled30 locationsNCT06542250
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
B-cell Malignancies
Sheba Medical Center50 enrolled1 locationNCT07135466
Recruiting
Phase 1Phase 2
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute100 enrolled4 locationsNCT03125577
Recruiting
Phase 1Phase 2
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute200 enrolled2 locationsNCT03050190
Recruiting
Phase 1Phase 2
CD19/70 Bi-specific CAR-T Cell Therapy
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute30 enrolled1 locationNCT05436496
Recruiting
Phase 1Phase 2
CD19/79b Bi-specific CAR-T Cell Therapy
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute60 enrolled1 locationNCT05436509
Recruiting
Phase 1Phase 2
CD19/22 Bi-specific CAR-T Cell Therapy
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute60 enrolled1 locationNCT05432882